Cytogam 2.5g
Biological
CSL Behring
Total Payments
$1.1M
Transactions
33
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $1.1M | 33 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 33 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)(CMV) | CSL Behring | $1.1M | 0 |
| In vitro propagation of wild type human cytomegalovirus | CSL Behring | $2,570 | 0 |
| In vivo research in animal models of organ transplantation | CSL Behring | $2,570 | 0 |
Top Doctors Receiving Payments for Cytogam 2.5g
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Providence, RI | $1.1M | 33 |
Ad
Manufacturing Companies
- CSL Behring $1.1M
Product Information
- Type Biological
- Total Payments $1.1M
- Total Doctors 0
- Transactions 33
About Cytogam 2.5g
Cytogam 2.5g is a biological associated with $1.1M in payments to 0 healthcare providers, recorded across 33 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2017 to 2017. In 2017, $1.1M was paid across 33 transactions to 0 doctors.
The most common payment nature for Cytogam 2.5g is "Unspecified" ($1.1M, 100.0% of total).
Cytogam 2.5g is associated with 3 research studies, including "A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)(CMV)" ($1.1M).